CMSB Annual Report 2022 has been completed n will be presented to the shareholders at the coming AGM on 26/05/23.
CMPI (formerly known as Malaysia Phosphate Additives Sarawak Sdn Bhd) had already referred a dispute involving the PPA to the Asian International Arbitration Centre under the dispute resolution mechanism of the PPA. The disputed amount of Rm266 million has been disclosed as contingent liability in the Annual Report 2022.
CMSB , MPA (Malaysia Phosphate Additives) n Tradewinds Plantation set up CMPI with shareholding of 60%, 27% n 13% respectively. Khazanah has 40% shareholding in MPA.
Don't think SESCO would want to sink CMPI operations, causing financial n commercial harm to Sarawak industrial eco system.

No, it's not margin call as the price has been stable before Thursday sell down. Margin call only if price drops below the maintenance margin requirement. Smart money leaving, possibly due to high customers concentration, expensive as compared to peers - Master PE only 6, PPHB PE only 4.9 whilst DSS PE is 15.9.

Their top 5 clients constitute 70% of their revenue. If one big client cancel order, it will greatly impact their net profit. Dec qtr EPS dropped to only 0.75 Sen from 3.38 Sen in Sept qtr.

Heard CMSB dropped heavily due to news of subscription for a capital call of RM 315,649,514.00, for a total of 315,649,514 shares in Cahya Mata Phosphates (at Rm1.00 per share) . Some thought that the capital call was meant for CMSB, hence they sell. Stay invested - CMSB has net cash backing per share of 39.80 sen n RHB-OSK set its TP at Rm1.60.

Vizione Nov qtr results out soon. New projects in the pipeline.

MI reported a net profit of RM18.7m (+46% QoQ) in 2QFY22 (driven by customers’ capex expansions and the strengthening USD against both MYR and NTD , not sales of land), bringing its bottomline to RM31.5m (+6.4% YoY) in 1HFY22. Cash per share is 42 Sen, with minimal debts.

Latest Q2 report - high short term borrowing at Rm257.9 million n low cash flow. Why current borrowing so high?

Q1 2022 net profit Rm3.038 millions or 1.17 sen per share. Expect even better results for Q2 plus possible dividend of 1 sen, giving dividend yield of 4.35%

CMSB cost - only Rm157 mil. n selling for Rm527 mil , or 49 Sen per share. Expect special dividend.

Olympia - possible unlocking value in its property n financial assets.

Before rights issue, Vizione NTA is 56 sen, Cash at Bank n FD 42 million, long term bank borrowing 8 million , short term bank borrowing 37 million. With rights issues proceeds , Vizione will be able to clinch more jobs, now book orders more than Rm 3 billion.

Buy the warrant WE for duit Raya

The first SPA is for the acquisition of Oilfield and its nine subsidiaries as well as a 48% equity interest in Scomi KMC Sdn Bhd (“Scomi KMC”) from Scomi Energy for a cash consideration of RM13.5 million. The second SPA involves Oiltools International acquiring from Scomi Oiltools Sdn Bhd (Receiver & Manager appointed) (“SOSB”) a 4% equity interest in Scomi KMC, 25% equity interest in Scomi Oiltools Gulf W.L.L. and 25% equity interest in Continental Wire Cloth (Malaysia) Sdn Bhd (formerly known as Global Oilfield Products Sdn Bhd) for a cash consideration of RM2.6 million. Through the first and second SPAs, Oiltools will hold 52% equity interest in Scomi KMC.

The third SPA is for the acquisition of a 5-storey shop office located in Dataran Prima, Petaling Jaya, Selangor by Oilfield International from SOSB while the fourth SPA is for Oilfield International’s acquisition of the inventory and equipment from SOSB for a total cash consideration of RM3.0 million and RM1.9 million respectively.

For the period under review, Scomi Oilfield Ltd revenue was higher than the corresponding period
in the preceding year by approximately RM1.6 million. The marginal increase was
mainly attributed to the improving performance in India and Pakistan.
The Group reported a pre-tax loss of RM3.4 million for the period under review against
the pre-tax loss of RM29.4 million for the corresponding period. The higher pre-tax
loss in the preceding year was mainly a result of unrealised foreign exchange loss for
the period amounting to RM17.7 million.

Yesterday lots of RSS n PDTs short selling. Those who short by borrowing scrips will hv to buy back.

NTA - Rm2.80. Cash at Bank Rm545 millions or 51 sen . per share. Investment in associate company n joint venture - about Rm1.3 billions or 1.21 per share. Short term security investment - Rm407 millions or 21 sen per share. Not only quite safe, it's very undervalued due to its upcoming projects, govt approval for its cement price increase, better dividend payout ,etc ,etc

Texchem Q4 results going to be very good. Someone here mentioned Rm15 to 20 mil. Buy Texchem for its turnaround story n not it's acquisition story.

Expect strong Q4 - 7 to 12 mil

Think the additional LTIP at 15% of share capital to be priced at not more than 65.5 sen. It's Long Term Incentive Plan for directors , don't think they want to price too high .

Wong has proposed private placement since Sept 2021, so far no action. Now propose additional LTIP at 15% of share capital. Believe they won't price the PP n LTIP at above 60 sen

475,295,394 NEW ORDINARY SHARES IN SAUDEE GROUP BERHAD at 15 sen, 2 rights with 1 free warrant for 1 share, completed in May 2021. Total rights proceeds amounted to Rm71.294 millions, less corporate fees of Rm883k, balance = Rm70.411 millions or 9.8sen per share of enlarged capital of 716 million issued capital. The balance of Rm70.411 millions is for the repayment of loan, construction of cold rooms, expansion of production capacity, investment in similar business, etc. With the MCO n EMCO in force, Saudee will not be able to carry out their investment and spending plans. It's mind boggling that with a rights issue cash of at least 9.8 sen per enlarged share capital, some parties are actively pushing the shares down as if the company is going bankrupt. Bursa should investigate.

UBS , CS r collecting at 1.810 n 1.82. Surprise that EPF is not buying as return is about 10.5% for period of less than 6 months.

Post removed.Why?

Some shareholders have been complaining to the Board to lift Insas out of its value trap. If Board agrees to just give 5% of its holding in Inari as dividend in specie, based on the median price of Rm3.40 for Inari, the dividend in specie will gives about 15 sen per share to the 693K plus Insas shareholders. Then the value trap conundrum will be lifted. Fully agree with post on Insas intrinsic value n earnings forecast -

"Its Nta is rm 2.83 per share loh!

Its intrinsic value when inclusive of inari mark to market gain exceed rm 5.00 per share mah...!!

Insas has a net cash exceeding Rm 0.90 per share woh!

When comes to earnings based on half year result insas profits is already rm 148m or eps 22.2 sen loh! "

Inari will be paying at least 4.5 Sen dividend for 2021. Insas holding of 544.8 mil Inari shares wld mean Rm24.5 mil dividend income or 3.5 sen per share based on Insas share capital of 693 miil shares. It's stock broking n other business will also be paying good dividend this year. Funds will be collecting.

BNM has rejected Generali takeover of 70% stake last year as BNM does not favour foreigners taking majority stake in fin inst. Look like MPHB has to find local buyer to sell its stake.

Unless BNM agrees to let Generali take majority stake over the insurance business, MPHB is still deemed a fin co , must comply with the margin of solvency requirement, hence cannot pay out dividend.

Solution price hovered around 0.20 before vaccines news . NTA only 0.1244. News to supply 3.5 millions Cansino vaccines. Assuming margin of Rm10 per bottle. 3.5 millions bottles only Rm35 million or Rm0.09 per share. After 2021, may not need so many vaccinations. ESOS
conversion to share is only Rm0.20. Need to be cautious.

Sale by Ng is not tru open market , but off market direct deal.. Expect new shareholder to come in.

SPA extended again for another 3 months to April 2021. No good governance company takes 1 year to complete the SPA. If unable to agree, should state reasons n not keeping shareholders in the dark. It may not be a bad thing as palm oil prices hv skyrocketed.

MOSTI list of 5 vaccines suppliers r meant for Malaysian. They are given free n no middle men. The 3 millions plus foreign workers or their bosses must pay for the vaccines. Sinopharm, strong contender to clinch contract. Kanger m Titijaya may benefit.

There r more than 3 millions foreign workers in Malaysia. Sinopharm may be roped in to supply to the foreigners , n the foreigners hv to pay for the dosage . Kanger n Titijaya may benefit.

Permaju n Ipmuda invest in solar business, their share price soar. GFM invest in solar business, the share price dives.

Something brewing in Ewein?

Their precision, tool n die division diversifying into high end e & e products?

Some bloggers forecast 4th qtr to be very good at 34.8 sen n full year 2021 at Rm1.74. Target price based on PE 20 Rm34.83. This means that for the next 20 years, Topglov will be making EPS of Rm1.74 every year. Russian vaccines hv potential, so are the various Chinese n US vaccines. Most probably the vaccines will be available by end of 2021. The EPS for the next 19 years will nosedive to below 50 sen. Most investors will only target a10 years time horizon to recoup their cost of investment. Assuming no change in EPS. a 10 years target will only value Topglov at Rm17.40 only.

Bornoil making huge gain in their gold trading. The 2nd quarter result is forecasted to be good n even better for the 3rd quarter. It's warrant price of 0.015 is a good entry price.

And NTA at around Rm 1.26

Think their div reinvestment policy dampens its price. Sad becos its asset quality is good, with sound revenue growth , adequate loss/loss cover, etc.

Agree that the dividend share reinvestment plan is a stupid idea. It just reflects poorly on the management. U cannot allow for the reinvestment plan if your share price is below Rm1.00. Most institutional funds will sell the mother at. 0.63 n above n opt for the dividend reinvestment at. 0.56, hence causing the price to spiral downwards.

IB put a share margin cap on glove counters for good reasons. Besides super high PE, it's also super risky. If one of their workers is tested positive for Covid19, that counter will drop super heavy.

Glove manufacturers employ lots of migrant workers. Hope all their migrant workers r screened for covid19 n none tested positive

MITI approved investors n pink form holders r selling. Think syndicates will stay on sideline for the time being.

U can see the DBT via ur own desktop or laptop. Ur dealer or remisier shd be able to guide u. PDT transactions r confidential. DBT could either be a crossing or married deal. 124.733 millions crossed at average price of 0.1708 . Why? Could it be big investors cashing out big time, so they go off market to cross so as not to disturb the primary market ? Or they crossed to some parties so that the parties have the liquidity to play the counter? Only time can tell.

Istone. Direct business transaction 124.733 millions done at average price of 0.1708. Be careful even though counter closed at. 245. Lots of stockists got burned. Luckily for the Proprietary Day Traders (PDT), they r not allowed to trade in ACE counters. Only the syndicates win. Heard that the PDTs got hit badly trading in UCW. However syndicates won big. Not sure how much price will dive at maturity of their financing period.

Direct Business Transaction or DBT. U can see them in your trading e trading platform page. Not sure, ask ur dealer to guide u.

Direct business transaction 124.733 millions done at average price of 0.1708. Be careful even though counter closed at. 245. Lots of stockists got burned. Luckily for the Proprietary Day Traders (PDT), they r not allowed to trade in ACE counters. Only the syndicates win. Heard that the PDTs got hit badly trading in UCW. However syndicates won big. Not sure how much price will dive at maturity of their financing
period.

There r more than 20 syndicates pushing up or pulling down the IPO shares. Hv to be careful. They spread all kinds of news to make fast money using share margins. discretionary financing, bank borrowings, etc to trade. These r short term financing. Once loans mature n they call in d loans, price will drop. Good example is MI, Keyasic, etc. As they push up, they can also push down to collect cheaply, like LHI whose forecast is expected to show good 3rd qtr results , their Vietnamese n Philippines chicken n feedmills operations r running at full capacity, etc. In Malaysia n Spore, they r increasing capacity, esp their rte, rtc, etc, n supply to KFC, etc. Most investment banks value LHI around 1.40

There r more than 20 syndicates pushing up or pulling down the IPO shares. Hv to be careful. They spread all kinds of news to make fast money using share margins. discretionary financing, bank borrowings, etc to trade. These r short term financing. Once loans mature n they call in d loans, price will drop. Good example is MI, Keyasic, etc. As they push up, they can also push down to collect cheaply, like LHI whose forecast is expected to show good 3rd results , their Vietnamese n Philippines chicken n feedmills operations r running at full capacity, etc. In Malaysia n Spore, they r increasing capacity, esp their rte, etc, n supply to KFC, etc.

Apart from enhancing production capacity as well as efficiency, UWC intends to automate some of the repetitive and laborious tasks in its production processes and implement an automated material handling system, besides expanding its service offerings to plating surface treatment services post-IPO. We derive a fair value of RM0.96 based on a c.13x PE multiple to its FY2020F EPS of 7.4 sen. The IPO is expected to raise approximately RM57.4m from the issuance of 70.0m new shares. Besides utilising 56.0% of the proceeds for the purchase of new CNC machines as well as industrial robotic arms and material handling system, 5.0% of the proceeds are allocated for working capital that are earmarked for long term future growth.

Most Investment banks value UWC at 1.10 to 1.15.Hope tmr force selling will not cause d price to overshoot on d downside.